Mohammed Bazuqamah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammed Bazuqamah has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Abrar K. Thabit
Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 22254, Saudi Arabia
3 shared publications - Ahmed Mohamed Badheeb
Oncology, King Khalid Hospital, Najran, SAU
2 shared publications Alaa Elhendawy
2 shared publicationsAli Garbo
Laboratory Department, King Khaled Hospital, Najran, Saudi Arabia
2 shared publicationsDalya Atallah
2 shared publicationsFatimah Alturki
2 shared publications
Latest Publications
- Open Access
- 7 May 2026
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 20 (1)
Breaking the serologic rule: chronic hepatitis B with simultaneous HBsAg and anti-HBs positivity—a case report
Background: Chronic hepatitis B virus (HBV) infection continues to pose a significant global disease burden, because of its potential progression to liver cirrhosis and hepatocellular carcinoma (HCC). Worldwide, more than 250 million individuals are estimated to be living with chronic HBV infection . Under standard serologic interpretation, the presence of hepatitis B surface antigen (HBsAg) signifies ongoing infection, whereas antibodies to hepatitis B surface antigen (anti-HBs) are generally associated with viral clearance or protective immunity. The simultaneous presence of both markers is rare and may lead to misinterpretation of serologic results, particularly when identified incidentally during routine screening in a primary care settings. Case presentation: We describe a 60-year-old Saudi woman with an asymptomatic chronic HBV infection incidentally identified during routine pre-colonoscopy screening in a primary care setting. Laboratory testing revealed reactive HBsAg, total anti-HBc positivity, reactive anti-HBs titer, and HBV DNA level was 275 IU/mL consistent with low-level viremia. Liver enzymes were mildly elevated on prior testing subsequently normalized on follow- up. Transient elastography demonstrated no evidence of hepatic fibrosis or steatosis. The patient had no history of HBV vaccination, blood transfusions, liver disease, or recognized high-risk exposures, including intravenous drug use or high-risk sexual or household contact. Conclusion: This case highlights a diagnostic pitfall in HBV serology, as concurrent HBsAg and anti-HBs positivity does not indicate viral clearance and may reflect immune escape mutations, viral heterogeneity, or host immune factors. Recognition of this rare serologic profile is particularly important for primary care physicians, as accurate interpretation requires integration of serologic, virologic, and clinical data, particularly in asymptomatic patients identified through routine screening. This ensure appropriate diagnosis, long-term surveillance, and risk stratification. Clinicians should remain vigilant when encountering this rare serologic profile to guide appropriate referral and follow-up.
- 7 May 2026
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 20 (1)
Open AccessBreaking the serologic rule: chronic hepatitis B with simultaneous HBsAg and anti-HBs positivity—a case report
Background: Chronic hepatitis B virus (HBV) infection continues to pose a significant global disease burden, because of its potential progression to liver cirrhosis and hepatocellular carcinoma (HCC). Worldwide, more than 250 million individuals are estimated to be living with chronic HBV infection . Under standard serologic interpretation, the presence of hepatitis B surface antigen (HBsAg) signifies ongoing infection, whereas antibodies to hepatitis B surface antigen (anti-HBs) are generally associated with viral clearance or protective immunity. The simultaneous presence of both markers is rare and may lead to misinterpretation of serologic results, particularly when identified incidentally during routine screening in a primary care settings. Case presentation: We describe a 60-year-old Saudi woman with an asymptomatic chronic HBV infection incidentally identified during routine pre-colonoscopy screening in a primary care setting. Laboratory testing revealed reactive HBsAg, total anti-HBc positivity, reactive anti-HBs titer, and HBV DNA level was 275 IU/mL consistent with low-level viremia. Liver enzymes were mildly elevated on prior testing subsequently normalized on follow- up. Transient elastography demonstrated no evidence of hepatic fibrosis or steatosis. The patient had no history of HBV vaccination, blood transfusions, liver disease, or recognized high-risk exposures, including intravenous drug use or high-risk sexual or household contact. Conclusion: This case highlights a diagnostic pitfall in HBV serology, as concurrent HBsAg and anti-HBs positivity does not indicate viral clearance and may reflect immune escape mutations, viral heterogeneity, or host immune factors. Recognition of this rare serologic profile is particularly important for primary care physicians, as accurate interpretation requires integration of serologic, virologic, and clinical data, particularly in asymptomatic patients identified through routine screening. This ensure appropriate diagnosis, long-term surveillance, and risk stratification. Clinicians should remain vigilant when encountering this rare serologic profile to guide appropriate referral and follow-up.
- Open Access
- 6 May 2026
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (6) , 103249
First cluster of relapsing fever compatible with louse-borne transmission in southern Saudi Arabia: An eight-case series from Najran
- 6 May 2026
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (6) , 103249
Open AccessFirst cluster of relapsing fever compatible with louse-borne transmission in southern Saudi Arabia: An eight-case series from Najran
- Open Access
- 19 April 2026
- Published by Springer Nature in Cureus
- Vol. 18 (4)
Infection Patterns and Predictors of 28-Day Mortality Among Cancer Patients in Najran, Saudi Arabia: A 10-Year Retrospective Cohort Analysis
- 19 April 2026
- Published by Springer Nature in Cureus
- Vol. 18 (4)
Open AccessInfection Patterns and Predictors of 28-Day Mortality Among Cancer Patients in Najran, Saudi Arabia: A 10-Year Retrospective Cohort Analysis
- Open Access
- 28 February 2025
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 152
National Surveillance of Antimicrobial Resistance to Pseudomonas aeruginosa (PA) and Acinetobacter baumannii (AB) in Saudi Arabia in 2022-2023
- 28 February 2025
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 152
Open AccessNational Surveillance of Antimicrobial Resistance to Pseudomonas aeruginosa (PA) and Acinetobacter baumannii (AB) in Saudi Arabia in 2022-2023
- Open Access
- 19 February 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (2) , 209
A National Surveillance of the Antibiotic Susceptibility of Acinetobacter baumannii in Saudi Arabia
Most surveillance studies in Saudi Arabia have been single-centered or did not use the gold standard broth microdilution (BMD) antimicrobial susceptibility test. This is the first study from Saudi Arabia to evaluate the resistance profiles of Acinetobacter baumannii by using BMD on a national level. Between November 2022 and April 2023, isolates from several infection sites were collected from seven hospitals in seven regions of Saudi Arabia. On testing days, BMD was done following Clinical Laboratory Standards Institute standards. Antibiotic susceptibility percentages and MIC50 and MIC90 were calculated. One hundred A. baumannii isolates were included. The highest susceptibility was to tigecycline (39%) and aminoglycosides (22–25%). The MIC90 of all antibiotics were higher than the resistance breakpoint. All isolates (100%) were multidrug-resistant, of which 52% were classified as extensive-drug-resistant, and 42% were identified as pandrug-resistant. The isolates collected from the ear, peritoneal fluid, and the cerebrospinal fluid were all XDR, while 2/3 of the urine isolates (10/15; 66.7%), more than 1/2 of the skin/soft tissue and respiratory isolates (9/16; 56.3% and 22/43; 51.7%, respectively), and 3/8 (37.5%) of the blood isolates met this definition. Conversely, PDR isolates made up 5/8 of blood isolates (62.5%), 8/15 of body fluid isolates (57.14%), and 19/43 (44.2%) of respiratory isolates. A. baumannii showed a surprisingly high resistance to multiple commonly used antibiotics. Infection control policies and antimicrobial stewardship should be implemented by hospitals throughout the country to improve treatment, track resistance trends with local antibiograms, and prevent the development of resistant strains.
- 19 February 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (2) , 209
Open AccessA National Surveillance of the Antibiotic Susceptibility of Acinetobacter baumannii in Saudi Arabia
Most surveillance studies in Saudi Arabia have been single-centered or did not use the gold standard broth microdilution (BMD) antimicrobial susceptibility test. This is the first study from Saudi Arabia to evaluate the resistance profiles of Acinetobacter baumannii by using BMD on a national level. Between November 2022 and April 2023, isolates from several infection sites were collected from seven hospitals in seven regions of Saudi Arabia. On testing days, BMD was done following Clinical Laboratory Standards Institute standards. Antibiotic susceptibility percentages and MIC50 and MIC90 were calculated. One hundred A. baumannii isolates were included. The highest susceptibility was to tigecycline (39%) and aminoglycosides (22–25%). The MIC90 of all antibiotics were higher than the resistance breakpoint. All isolates (100%) were multidrug-resistant, of which 52% were classified as extensive-drug-resistant, and 42% were identified as pandrug-resistant. The isolates collected from the ear, peritoneal fluid, and the cerebrospinal fluid were all XDR, while 2/3 of the urine isolates (10/15; 66.7%), more than 1/2 of the skin/soft tissue and respiratory isolates (9/16; 56.3% and 22/43; 51.7%, respectively), and 3/8 (37.5%) of the blood isolates met this definition. Conversely, PDR isolates made up 5/8 of blood isolates (62.5%), 8/15 of body fluid isolates (57.14%), and 19/43 (44.2%) of respiratory isolates. A. baumannii showed a surprisingly high resistance to multiple commonly used antibiotics. Infection control policies and antimicrobial stewardship should be implemented by hospitals throughout the country to improve treatment, track resistance trends with local antibiograms, and prevent the development of resistant strains.
- 15 January 2025
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 111 (3) , 116689
Antibiotics prescribing patterns before vs after minimum inhibitory concentration suppression: A quasi-experimental study
- 15 January 2025
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 111 (3) , 116689
Antibiotics prescribing patterns before vs after minimum inhibitory concentration suppression: A quasi-experimental study
- Open Access
- 1 January 2025
- Published by Wiley in Global Health, Epidemiology and Genomics
- Vol. 2025 (1) , 5042190
Identification of Significant Mutations in Spike Protein of SARS‐CoV‐2 Variants of Concern and the Discovery of Potent Inhibitors
Background: SARS‐CoV‐2 is a positive‐sense single‐stranded RNA virus that has a propensity for infecting epithelial cells and the respiratory system. The two important proteins, structural and nonstructural proteins, make the architecture of this virus. Aim: This research aimed at studying significant mutations in spike protein of SARS‐CoV‐2 variants of concern (VoCs) and finding shared mutations among omicron and other four variants (alpha, beta, gamma, and delta). The purpose of this study was to draw structural comparisons between wild type and mutant proteins, followed by identifying potent inhibitors (ligand) that could be used against SARS‐CoV‐2 spike protein and its latest omicron VoC. Methodology: In this research, we had studied 16 major mutations as well as shared mutations (6) present in spike region of SARS‐CoV‐2. Subsequently, we determined the structure of the wild‐type SARS‐CoV‐2 protein from the Protein Data Bank (PDB) with the ID 7R4I. Furthermore, the structure of the mutant protein of SARS‐CoV‐2 omicron variant was modeled in SWISS‐MODEL. The ligand dataset for spike protein of SARS‐CoV‐2 was also collected from literature and different databases. Both wild type and mutant proteins were docked with ligand database in Molecular Operating Environment (MOE). The docking analysis was performed, and two best ligand molecules, AZ_2 and AZ_13, were finalized based on their energy values, interactions, and docking scores to be used against our wild and mutant proteins. Results: AZ_2 demonstrated a docking score of −6.1753 in MOE, with energy values of −4.3889 and −6.1753. It formed key hydrogen bond interactions. AZ_13 showed a docking score of −5.9, with energy values of −9.3 and −5.9, forming hydrogen donor and acceptor interactions with Asp950 (3.06 Å), Ile312 (3.13 Å), and Glu309 (3.27 Å). These interactions suggest strong binding affinity and potential efficacy. Thus, present research work emphasized on identification of significant mutations and finding a potent target‐based drug against SARS‐CoV‐2 and its omicron variant. Outcomes: Based on this computational analysis performed, it is suggested that proposed compound can be used as remedy against SARS‐CoV‐2 and its omicron variant.
- 1 January 2025
- Published by Wiley in Global Health, Epidemiology and Genomics
- Vol. 2025 (1) , 5042190
Open AccessIdentification of Significant Mutations in Spike Protein of SARS‐CoV‐2 Variants of Concern and the Discovery of Potent Inhibitors
Background: SARS‐CoV‐2 is a positive‐sense single‐stranded RNA virus that has a propensity for infecting epithelial cells and the respiratory system. The two important proteins, structural and nonstructural proteins, make the architecture of this virus. Aim: This research aimed at studying significant mutations in spike protein of SARS‐CoV‐2 variants of concern (VoCs) and finding shared mutations among omicron and other four variants (alpha, beta, gamma, and delta). The purpose of this study was to draw structural comparisons between wild type and mutant proteins, followed by identifying potent inhibitors (ligand) that could be used against SARS‐CoV‐2 spike protein and its latest omicron VoC. Methodology: In this research, we had studied 16 major mutations as well as shared mutations (6) present in spike region of SARS‐CoV‐2. Subsequently, we determined the structure of the wild‐type SARS‐CoV‐2 protein from the Protein Data Bank (PDB) with the ID 7R4I. Furthermore, the structure of the mutant protein of SARS‐CoV‐2 omicron variant was modeled in SWISS‐MODEL. The ligand dataset for spike protein of SARS‐CoV‐2 was also collected from literature and different databases. Both wild type and mutant proteins were docked with ligand database in Molecular Operating Environment (MOE). The docking analysis was performed, and two best ligand molecules, AZ_2 and AZ_13, were finalized based on their energy values, interactions, and docking scores to be used against our wild and mutant proteins. Results: AZ_2 demonstrated a docking score of −6.1753 in MOE, with energy values of −4.3889 and −6.1753. It formed key hydrogen bond interactions. AZ_13 showed a docking score of −5.9, with energy values of −9.3 and −5.9, forming hydrogen donor and acceptor interactions with Asp950 (3.06 Å), Ile312 (3.13 Å), and Glu309 (3.27 Å). These interactions suggest strong binding affinity and potential efficacy. Thus, present research work emphasized on identification of significant mutations and finding a potent target‐based drug against SARS‐CoV‐2 and its omicron variant. Outcomes: Based on this computational analysis performed, it is suggested that proposed compound can be used as remedy against SARS‐CoV‐2 and its omicron variant.
- Open Access
- 12 November 2024
- Published by Springer Nature in Discover Medicine
- Vol. 1 (1) , 1-14
Prevalence of multidrug-, extensively drug-, and pandrug-resistant bacteria in clinical isolates from King Khaled Hospital, Najran, Saudi Arabia
Background: Saudi Arabia faces a growing antimicrobial resistance (AMR) problem, exacerbated by the widespread use of antibiotics in clinical and agricultural settings. Despite this, AMR surveillance has been limited, particularly in regions like Najran, making this study critical for informing local and national public health strategies. Aim: This study explored the prevalence of multidrug-resistant, extensively drug-resistant, and Pandrug-resistant bacteria in Najran, Saudi Arabia. Study design: This is a cross-sectional study. Methods: This study included 559 diverse clinical samples (urine, wound, etc.) collected from various departments in King Khaled Hospital, Saudi Arabia. The Phoenix BD instrument was used for complete bacterial identification and antibiotic sensitivity testing. Demographic and clinical data were analyzed statistically. Results: Of the 559 samples, the culture positivity rates were as follows: 51% for Escherichia coli, 22% for Staphylococcus aureus, 14% for Klebsiella pneumoniae, 6% for Acinetobacter baumannii, 6% for Pseudomonas aeruginosa, and 1% for Enterococcus faecium. Majority of the cases were from male (57%), and age 50+ (59%) recorded highest cases. Participants from outpatient department (OPD) ward recorded the highest (56%) cases, while urine sample recorded the highest (49%) cases. About 84% of the isolates were multidrug‑resistance (MDR), 10% were extensively drug‑resistance (XDR), and 6% pandrug‑resistance (PDR). Our analysis showed high sensitivity to Oxazolidonone, Tetracycline, carbapenems, Lipopeptide, Aminoglycopeptide classes of antibiotics. Conclusions: The study revealed a high prevalence of drug resistance, highlighting the critical importance of continued surveillance and research to mitigate the spread of antimicrobial resistance and preserve the effectiveness of existing therapies.
- 12 November 2024
- Published by Springer Nature in Discover Medicine
- Vol. 1 (1) , 1-14
Open AccessPrevalence of multidrug-, extensively drug-, and pandrug-resistant bacteria in clinical isolates from King Khaled Hospital, Najran, Saudi Arabia
Background: Saudi Arabia faces a growing antimicrobial resistance (AMR) problem, exacerbated by the widespread use of antibiotics in clinical and agricultural settings. Despite this, AMR surveillance has been limited, particularly in regions like Najran, making this study critical for informing local and national public health strategies. Aim: This study explored the prevalence of multidrug-resistant, extensively drug-resistant, and Pandrug-resistant bacteria in Najran, Saudi Arabia. Study design: This is a cross-sectional study. Methods: This study included 559 diverse clinical samples (urine, wound, etc.) collected from various departments in King Khaled Hospital, Saudi Arabia. The Phoenix BD instrument was used for complete bacterial identification and antibiotic sensitivity testing. Demographic and clinical data were analyzed statistically. Results: Of the 559 samples, the culture positivity rates were as follows: 51% for Escherichia coli, 22% for Staphylococcus aureus, 14% for Klebsiella pneumoniae, 6% for Acinetobacter baumannii, 6% for Pseudomonas aeruginosa, and 1% for Enterococcus faecium. Majority of the cases were from male (57%), and age 50+ (59%) recorded highest cases. Participants from outpatient department (OPD) ward recorded the highest (56%) cases, while urine sample recorded the highest (49%) cases. About 84% of the isolates were multidrug‑resistance (MDR), 10% were extensively drug‑resistance (XDR), and 6% pandrug‑resistance (PDR). Our analysis showed high sensitivity to Oxazolidonone, Tetracycline, carbapenems, Lipopeptide, Aminoglycopeptide classes of antibiotics. Conclusions: The study revealed a high prevalence of drug resistance, highlighting the critical importance of continued surveillance and research to mitigate the spread of antimicrobial resistance and preserve the effectiveness of existing therapies.